Outcomes of adult critically ill patients with hemophagocytic lymphohistiocytosis in united states-analysis from an administrative database from 2007 to 2015

被引:0
|
作者
Kumar, Gagan [1 ]
Hererra, Martin [2 ]
Patel, Dhaval [1 ]
Nanchal, Rahul [3 ]
Guddati, Achuta K. [4 ]
机构
[1] Northeast Georgia Hlth Syst, Dept Pulm & Crit Care, Gainesville, GA 30501 USA
[2] Northeast Georgia Hlth Syst, Dept Internal Med, Gainesville, GA 30501 USA
[3] Med Coll Wisconsin, Div Pulm & Crit Care, Milwaukee, WI 53226 USA
[4] Augusta Univ, Dept Hematol & Oncol, Augusta, GA 30912 USA
来源
AMERICAN JOURNAL OF BLOOD RESEARCH | 2020年 / 10卷 / 06期
关键词
Hemophagocytic lymphohistiocytosis; hemophagocytic syndrome; epidemiology; critical illness;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Severe infections caused by the novel coronavirus 2 display similarities to secondary hemophagocytic lymphohistiocytosis (HLH). However, HLH is a rare disease and has not been well described in critically ill patients. Methods: We used the Nationwide Inpatient Sample (NIS), the largest all-payer inpatient care database publicly available in the United States to identify all adult discharges with Hemophagocytic syndrome (ICD-9 CM code 288.4) between 2007 and 2015. Critical illness was considered present if patient had either ICD-9 CM code indicating the requirement of invasive mechanical ventilation or the presence of shock. We used ICD-9-CM codes to identify various infections (inf-HLH), malignancies (mal-HLH) and autoimmune diseases associated with HLH (MAS-HLH) and classified them in their respective groups. Primary outcome was in-hospital mortality in critically ill patients. We developed multivariable regression model to examine variables associated with mortality in critically ill HLH patients. P value was kept at < 0.05. Results: Of the 7420 (95% CI 6959-7881) estimated discharges with HLH, 2313 (31%) were critically ill. Of the critically ill patients, 442 (34%) were mal-HLH, 422 (43.3%) were inf-HLH, 403 (30.7%) were MAS-HLH and 1046 (27.3%) were unable to be classified. In hospital mortality rates were 6.4% in non-critically ill and 48.4% in critically ill patients. Among the subtypes of HLH, in-hospital mortality was 53% in mal-HLH, 49.4% in inf-HLH, 26% in MAS-HLH and 54.6% in unclassified group. On multivariable regression analysis, development of acute renal failure requiring hemodialysis (OR 2.06, 95% CI 1.29-3.3, P=0.002) and acute hepatic failure (OR 2.21, 95% CI 1.38-3.52, P=0.001) were significantly associated with higher mortality. Conclusion: Inpatient mortality of critically ill patients is remarkably high. Patients with MAS-HLH had better outcomes when compared to other groups of HLH.
引用
收藏
页码:330 / +
页数:11
相关论文
共 50 条
  • [1] Outcomes Of Etoposide Based Treatment Of Acquired Hemophagocytic Lymphohistiocytosis In Adult Critically Ill Patients
    Sparacino, N. L.
    Raschke, R.
    Curry, S. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [2] Treatment and Mortality of Hemophagocytic Lymphohistiocytosis in Adult Critically Ill Patients: A Systematic Review With Pooled Analysis
    Knaak, Cornelia
    Schuster, Friederike S.
    Nyvlt, Peter
    Spies, Claudia
    Feinkohl, Insa
    Beutel, Gernot
    Schenk, Thomas
    La Rosee, Paul
    Janka, Gritta
    Brunkhorst, Frank M.
    Keh, Didier
    Lachmann, Gunnar
    CRITICAL CARE MEDICINE, 2020, 48 (11) : E1137 - E1146
  • [3] Ruxolitinib, intravenous immunoglobulin and high-dose corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis
    Scholz, L.
    Posch, F.
    Schulz, E.
    Gornicec, M.
    Rosenkranz, A. R.
    Schilcher, G.
    Reisinger, A.
    Krause, R.
    Hatzl, S.
    MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2023, 118 (05)
  • [4] Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis
    Wohlfarth, Philipp
    Agis, Hermine
    Gualdoni, Guido A.
    Weber, Johannes
    Staudinger, Thomas
    Schellongowski, Peter
    Robak, Oliver
    JOURNAL OF INTENSIVE CARE MEDICINE, 2019, 34 (09) : 723 - 731
  • [5] Hemophagocytic lymphohistiocytosis in adult and pediatric patients Perspectives from a tertiary care center
    Nguyen, Minh H. N.
    Baker, Melissa
    Spoden, Tahnee
    Rivera-Valenzuela, Maritza Gisel
    Azmeh, Roua
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (04) : 507 - 509
  • [6] TRENDS, PREDICTORS, AND OUTCOMES OF CRITICALLY ILL PATIENTS WITH SICKLE CELL DISEASE IN THE UNITED STATES
    Nzeako, Tochukwu
    Adeniran, Olayemi
    Eneh, Chukwuka
    Spencer, Joann
    CHEST, 2024, 166 (04) : 146A - 146A
  • [7] Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database
    Liang, Qihong
    Li, Lulan
    Chen, Kerong
    An, Sheng
    Deng, Zhiya
    Li, Jiaxin
    Zhou, Shiyu
    Chen, Zhongqing
    Zeng, Zhenhua
    An, Shengli
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2023, 28
  • [8] Survival Outcomes Following the Use of Extracorporeal Membrane Oxygenation as a Rescue Technology in Critically Ill Patients: Results From Pennsylvania 2007-2015
    Huesch, Marco D.
    Foy, Andrew
    Brehm, Christoph
    CRITICAL CARE MEDICINE, 2018, 46 (01) : E87 - E90
  • [9] Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database
    Neupane, Niraj
    Shikhrakar, Shreeja
    Thapa, Sangharsha
    Shrestha, Asis
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Circadian rhythm in critically ill patients: Insights from the eICU Database
    Beyer, Sebastian E.
    Salgado, Catia
    Garcao, Ines
    Celi, Leo Anthony
    Vieira, Susana
    CARDIOVASCULAR DIGITAL HEALTH JOURNAL, 2021, 2 (02): : 118 - 125